CEPI will fund the initiative under its USD 200 million programme to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other betacoronaviruses.
CEPI on Tuesday said it will provide up to USD 19.3 million (about Rs 149 crore) to Bharat Biotech International, the University of Sydney, and Switzerland-based ExcellGene SA for the development of a "variant-proof" SARS-CoV-2 vaccine candidate.